Qiagen maintained at sell by Merrill

Qiagen NV was kept at its sell rating by Merrill Lynch analyst Erica Whittaker after the company beat Merrill's and consensus forecasts on the top and bottom line. The company had net sales $109 million, versus Merrill's estimate of $102 million and consensus of $104 million. Adjusted earnings per share of $0.13 beat the analyst's estimate of $0.11 and consensus of $0.12. Shares of the Venlo, The Netherlands, biotechnology company were down 19 cents, or 1.24%, at $15.09 on volume of 602,771 shares versus the three-month running average of 274,616 shares. (Nasdaq: QGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.